Analisi di budget impact del biosimilare di etanercept: lo scenario italiano
Author:
Affiliation:
1. Health Publishing & Services Srl, Milano, Italy
2. Dermatologia, Azienda Ospedaliera Universitaria Integrata, Verona, Italy
3. Reumatologia, ASST Spedali Civili, Brescia, Italy
Publisher
Aboutscience Srl
Subject
Health Policy
Link
http://journals.sagepub.com/doi/pdf/10.1177/2284240318766804
Reference19 articles.
1. “KISS” — Embracing Routine Patient Assessment
2. The burden of rheumatoid arthritis and access to treatment: health burden and costs
3. Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima basata su una metodologia probabilistica di Cost of Illness
4. Social cost of chronic pain in Italy
5. Costs and quality of life in multiple sclerosis in Europe: method of assessment and analysis
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Good practices for the development of budget impact models at regional level;Global and Regional Health Technology Assessment;2023-06-26
2. Biosimilars approved for psoriasis treatment in Europe;PONS - medicinski casopis;2023
3. Health technology assessment of biosimilars worldwide: a scoping review;Health Research Policy and Systems;2020-08-26
4. Biological Therapies in Immune-Mediated Inflammatory Diseases: Can Biosimilars Reduce Access Inequities?;Frontiers in Pharmacology;2019-03-28
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3